Home Tags Drug-to-antibody ratio

Tag: drug-to-antibody ratio

Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...

National Institutes of Health Awards Development Grant to Applied BioMath for...

The U.S. National Institute of Health has awarded a development grant to Applied BioMath for a software platform called Antibody-drug Conjugate (ADC) Workbench.  The...
Photo: San Deigo Bay from Harbor Drive, San Diego, CA, USA. Photo Courtesy: This photo has been released into the public domain by its author, Jon Sullivan. This applies worldwide.

From First-in-Human to Post-Commercial: ADC Reference Materials and Specifications

The 2019 World ADC conference in San Diego, CA, held October 8 – 11, 2019, started with a day of 9 interactive workshops on...

Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma

Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...